Mechanisms of RND multidrug efflux pumps
RND (Resistance-Nodulation-Division) family transporters are widespread especially among Gram-negative bacteria, and catalyze the active efflux of many antibiotics and chemotherapeutic agents. They have very large periplasmic domains, and form tripartite complexes with outer membrane channels and pe...
Gespeichert in:
Veröffentlicht in: | Biochimica et biophysica acta 2009-05, Vol.1794 (5), p.769-781 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 781 |
---|---|
container_issue | 5 |
container_start_page | 769 |
container_title | Biochimica et biophysica acta |
container_volume | 1794 |
creator | Nikaido, Hiroshi Takatsuka, Yumiko |
description | RND (Resistance-Nodulation-Division) family transporters are widespread especially among Gram-negative bacteria, and catalyze the active efflux of many antibiotics and chemotherapeutic agents. They have very large periplasmic domains, and form tripartite complexes with outer membrane channels and periplasmic adaptor proteins. AcrAB–TolC complex of
Escherichia coli, which pumps out a very wide range of drugs, has been studied most intensively. Early studies showed that the transporter captures even those substrates that cannot permeate across the cytoplasmic membrane, such as dianionic β-lactams, suggesting that the capture can occur from the periplasm. It was also suggested that the capture occurs from the cytoplasmic membrane/periplasm interface, because most substrates contain a sizable hydrophobic domain; however, this may simply be a reflection of the nature of the binding site within AcrB. Genetic studies of chimeric transporters showed that much of the substrate specificity is determined by their periplasmic domains. Biochemical studies with intact cells recently led to the determination of the kinetic constants of AcrB for some β-lactams, and the result confirms the old prediction that AcrB is a rather slow pump. Reconstitution of purified AcrB and its relatives showed that the pump is a drug/proton antiporter, that AcrA strongly stimulates the activity of the pump, and that AcrB seems to have a highest affinity for conjugated bile salts. Structural study with mutants of the network of charged residues in the transmembrane domain showed that protonation here produced a far-reaching conformational change, which was found to be present in one of the protomers in the asymmetric crystal structure of the wild-type AcrB. The functional rotatory hypothesis then predicts that the drug bound in the periplasmic domain is extruded through this conformational change initiated by the protonation of one of the residues in the aforementioned network, an idea that was recently supported by disulfide cross-linking as well as by the behavior of linked AcrB protomers. |
doi_str_mv | 10.1016/j.bbapap.2008.10.004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_20672206</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1570963908003348</els_id><sourcerecordid>20672206</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-3e3adfdbf68f8b8a40b1cb30d34823a2160880e0d83469ae7f4b5d2a6ed54f0e3</originalsourceid><addsrcrecordid>eNp9kEtv2zAMx4Whw5Km-wbD4FPRizNKlmX5MmDoG0g7YOjOgixRiQK_JtlF9-3rIEGzXnYhCT7-JH-EfKGwpEDFt-2yqnSv-yUDkFNqCcA_kDmVhUwpz_nJFOcFpKXIyhk5jXELwKAo8k9kRktgoihgTi4e0Gx062MTk84lvx6vkmasB2_DuE7QuXp8Sfqx6eMZ-eh0HfHzwS_I75vrp8u7dPXz9v7yxyo1vGRDmmGmrbOVE9LJSmoOFTVVBjbjkmWaUQFSAoKVGRelxsLxKrdMC7Q5d4DZgnzf6_Zj1aA12A5B16oPvtHhr-q0V-8rrd-odfesmCiFnJ5dkPODQOj-jBgH1fhosK51i90YFQNRsMlMjXzfaEIXY0D3toSC2iFWW7VHrHaId9kJ8TT29d8Dj0MHpscPcML07DGoaDy2Bq0PaAZlO___Da-LNI81</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20672206</pqid></control><display><type>article</type><title>Mechanisms of RND multidrug efflux pumps</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Nikaido, Hiroshi ; Takatsuka, Yumiko</creator><creatorcontrib>Nikaido, Hiroshi ; Takatsuka, Yumiko</creatorcontrib><description>RND (Resistance-Nodulation-Division) family transporters are widespread especially among Gram-negative bacteria, and catalyze the active efflux of many antibiotics and chemotherapeutic agents. They have very large periplasmic domains, and form tripartite complexes with outer membrane channels and periplasmic adaptor proteins. AcrAB–TolC complex of
Escherichia coli, which pumps out a very wide range of drugs, has been studied most intensively. Early studies showed that the transporter captures even those substrates that cannot permeate across the cytoplasmic membrane, such as dianionic β-lactams, suggesting that the capture can occur from the periplasm. It was also suggested that the capture occurs from the cytoplasmic membrane/periplasm interface, because most substrates contain a sizable hydrophobic domain; however, this may simply be a reflection of the nature of the binding site within AcrB. Genetic studies of chimeric transporters showed that much of the substrate specificity is determined by their periplasmic domains. Biochemical studies with intact cells recently led to the determination of the kinetic constants of AcrB for some β-lactams, and the result confirms the old prediction that AcrB is a rather slow pump. Reconstitution of purified AcrB and its relatives showed that the pump is a drug/proton antiporter, that AcrA strongly stimulates the activity of the pump, and that AcrB seems to have a highest affinity for conjugated bile salts. Structural study with mutants of the network of charged residues in the transmembrane domain showed that protonation here produced a far-reaching conformational change, which was found to be present in one of the protomers in the asymmetric crystal structure of the wild-type AcrB. The functional rotatory hypothesis then predicts that the drug bound in the periplasmic domain is extruded through this conformational change initiated by the protonation of one of the residues in the aforementioned network, an idea that was recently supported by disulfide cross-linking as well as by the behavior of linked AcrB protomers.</description><identifier>ISSN: 1570-9639</identifier><identifier>ISSN: 0006-3002</identifier><identifier>EISSN: 1878-1454</identifier><identifier>DOI: 10.1016/j.bbapap.2008.10.004</identifier><identifier>PMID: 19026770</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>AcrA ; AcrB ; AcrD ; Bacterial Proteins - physiology ; Carrier Proteins - physiology ; Crystallography, X-Ray ; Disulfide cross-linking ; Drug Resistance, Bacterial - physiology ; Escherichia coli ; Escherichia coli Proteins - genetics ; Escherichia coli Proteins - physiology ; Kinetics ; Models, Molecular ; Multidrug Resistance-Associated Proteins - genetics ; Multidrug Resistance-Associated Proteins - physiology ; Mutagenesis, Site-Directed ; Mutation ; Phospholipids - metabolism ; Proton relay network ; Reconstitution ; TolC</subject><ispartof>Biochimica et biophysica acta, 2009-05, Vol.1794 (5), p.769-781</ispartof><rights>2008 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-3e3adfdbf68f8b8a40b1cb30d34823a2160880e0d83469ae7f4b5d2a6ed54f0e3</citedby><cites>FETCH-LOGICAL-c492t-3e3adfdbf68f8b8a40b1cb30d34823a2160880e0d83469ae7f4b5d2a6ed54f0e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1570963908003348$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,881,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19026770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nikaido, Hiroshi</creatorcontrib><creatorcontrib>Takatsuka, Yumiko</creatorcontrib><title>Mechanisms of RND multidrug efflux pumps</title><title>Biochimica et biophysica acta</title><addtitle>Biochim Biophys Acta</addtitle><description>RND (Resistance-Nodulation-Division) family transporters are widespread especially among Gram-negative bacteria, and catalyze the active efflux of many antibiotics and chemotherapeutic agents. They have very large periplasmic domains, and form tripartite complexes with outer membrane channels and periplasmic adaptor proteins. AcrAB–TolC complex of
Escherichia coli, which pumps out a very wide range of drugs, has been studied most intensively. Early studies showed that the transporter captures even those substrates that cannot permeate across the cytoplasmic membrane, such as dianionic β-lactams, suggesting that the capture can occur from the periplasm. It was also suggested that the capture occurs from the cytoplasmic membrane/periplasm interface, because most substrates contain a sizable hydrophobic domain; however, this may simply be a reflection of the nature of the binding site within AcrB. Genetic studies of chimeric transporters showed that much of the substrate specificity is determined by their periplasmic domains. Biochemical studies with intact cells recently led to the determination of the kinetic constants of AcrB for some β-lactams, and the result confirms the old prediction that AcrB is a rather slow pump. Reconstitution of purified AcrB and its relatives showed that the pump is a drug/proton antiporter, that AcrA strongly stimulates the activity of the pump, and that AcrB seems to have a highest affinity for conjugated bile salts. Structural study with mutants of the network of charged residues in the transmembrane domain showed that protonation here produced a far-reaching conformational change, which was found to be present in one of the protomers in the asymmetric crystal structure of the wild-type AcrB. The functional rotatory hypothesis then predicts that the drug bound in the periplasmic domain is extruded through this conformational change initiated by the protonation of one of the residues in the aforementioned network, an idea that was recently supported by disulfide cross-linking as well as by the behavior of linked AcrB protomers.</description><subject>AcrA</subject><subject>AcrB</subject><subject>AcrD</subject><subject>Bacterial Proteins - physiology</subject><subject>Carrier Proteins - physiology</subject><subject>Crystallography, X-Ray</subject><subject>Disulfide cross-linking</subject><subject>Drug Resistance, Bacterial - physiology</subject><subject>Escherichia coli</subject><subject>Escherichia coli Proteins - genetics</subject><subject>Escherichia coli Proteins - physiology</subject><subject>Kinetics</subject><subject>Models, Molecular</subject><subject>Multidrug Resistance-Associated Proteins - genetics</subject><subject>Multidrug Resistance-Associated Proteins - physiology</subject><subject>Mutagenesis, Site-Directed</subject><subject>Mutation</subject><subject>Phospholipids - metabolism</subject><subject>Proton relay network</subject><subject>Reconstitution</subject><subject>TolC</subject><issn>1570-9639</issn><issn>0006-3002</issn><issn>1878-1454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtv2zAMx4Whw5Km-wbD4FPRizNKlmX5MmDoG0g7YOjOgixRiQK_JtlF9-3rIEGzXnYhCT7-JH-EfKGwpEDFt-2yqnSv-yUDkFNqCcA_kDmVhUwpz_nJFOcFpKXIyhk5jXELwKAo8k9kRktgoihgTi4e0Gx062MTk84lvx6vkmasB2_DuE7QuXp8Sfqx6eMZ-eh0HfHzwS_I75vrp8u7dPXz9v7yxyo1vGRDmmGmrbOVE9LJSmoOFTVVBjbjkmWaUQFSAoKVGRelxsLxKrdMC7Q5d4DZgnzf6_Zj1aA12A5B16oPvtHhr-q0V-8rrd-odfesmCiFnJ5dkPODQOj-jBgH1fhosK51i90YFQNRsMlMjXzfaEIXY0D3toSC2iFWW7VHrHaId9kJ8TT29d8Dj0MHpscPcML07DGoaDy2Bq0PaAZlO___Da-LNI81</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Nikaido, Hiroshi</creator><creator>Takatsuka, Yumiko</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20090501</creationdate><title>Mechanisms of RND multidrug efflux pumps</title><author>Nikaido, Hiroshi ; Takatsuka, Yumiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-3e3adfdbf68f8b8a40b1cb30d34823a2160880e0d83469ae7f4b5d2a6ed54f0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>AcrA</topic><topic>AcrB</topic><topic>AcrD</topic><topic>Bacterial Proteins - physiology</topic><topic>Carrier Proteins - physiology</topic><topic>Crystallography, X-Ray</topic><topic>Disulfide cross-linking</topic><topic>Drug Resistance, Bacterial - physiology</topic><topic>Escherichia coli</topic><topic>Escherichia coli Proteins - genetics</topic><topic>Escherichia coli Proteins - physiology</topic><topic>Kinetics</topic><topic>Models, Molecular</topic><topic>Multidrug Resistance-Associated Proteins - genetics</topic><topic>Multidrug Resistance-Associated Proteins - physiology</topic><topic>Mutagenesis, Site-Directed</topic><topic>Mutation</topic><topic>Phospholipids - metabolism</topic><topic>Proton relay network</topic><topic>Reconstitution</topic><topic>TolC</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nikaido, Hiroshi</creatorcontrib><creatorcontrib>Takatsuka, Yumiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biochimica et biophysica acta</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nikaido, Hiroshi</au><au>Takatsuka, Yumiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanisms of RND multidrug efflux pumps</atitle><jtitle>Biochimica et biophysica acta</jtitle><addtitle>Biochim Biophys Acta</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>1794</volume><issue>5</issue><spage>769</spage><epage>781</epage><pages>769-781</pages><issn>1570-9639</issn><issn>0006-3002</issn><eissn>1878-1454</eissn><abstract>RND (Resistance-Nodulation-Division) family transporters are widespread especially among Gram-negative bacteria, and catalyze the active efflux of many antibiotics and chemotherapeutic agents. They have very large periplasmic domains, and form tripartite complexes with outer membrane channels and periplasmic adaptor proteins. AcrAB–TolC complex of
Escherichia coli, which pumps out a very wide range of drugs, has been studied most intensively. Early studies showed that the transporter captures even those substrates that cannot permeate across the cytoplasmic membrane, such as dianionic β-lactams, suggesting that the capture can occur from the periplasm. It was also suggested that the capture occurs from the cytoplasmic membrane/periplasm interface, because most substrates contain a sizable hydrophobic domain; however, this may simply be a reflection of the nature of the binding site within AcrB. Genetic studies of chimeric transporters showed that much of the substrate specificity is determined by their periplasmic domains. Biochemical studies with intact cells recently led to the determination of the kinetic constants of AcrB for some β-lactams, and the result confirms the old prediction that AcrB is a rather slow pump. Reconstitution of purified AcrB and its relatives showed that the pump is a drug/proton antiporter, that AcrA strongly stimulates the activity of the pump, and that AcrB seems to have a highest affinity for conjugated bile salts. Structural study with mutants of the network of charged residues in the transmembrane domain showed that protonation here produced a far-reaching conformational change, which was found to be present in one of the protomers in the asymmetric crystal structure of the wild-type AcrB. The functional rotatory hypothesis then predicts that the drug bound in the periplasmic domain is extruded through this conformational change initiated by the protonation of one of the residues in the aforementioned network, an idea that was recently supported by disulfide cross-linking as well as by the behavior of linked AcrB protomers.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>19026770</pmid><doi>10.1016/j.bbapap.2008.10.004</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1570-9639 |
ispartof | Biochimica et biophysica acta, 2009-05, Vol.1794 (5), p.769-781 |
issn | 1570-9639 0006-3002 1878-1454 |
language | eng |
recordid | cdi_proquest_miscellaneous_20672206 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | AcrA AcrB AcrD Bacterial Proteins - physiology Carrier Proteins - physiology Crystallography, X-Ray Disulfide cross-linking Drug Resistance, Bacterial - physiology Escherichia coli Escherichia coli Proteins - genetics Escherichia coli Proteins - physiology Kinetics Models, Molecular Multidrug Resistance-Associated Proteins - genetics Multidrug Resistance-Associated Proteins - physiology Mutagenesis, Site-Directed Mutation Phospholipids - metabolism Proton relay network Reconstitution TolC |
title | Mechanisms of RND multidrug efflux pumps |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A30%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanisms%20of%20RND%20multidrug%20efflux%20pumps&rft.jtitle=Biochimica%20et%20biophysica%20acta&rft.au=Nikaido,%20Hiroshi&rft.date=2009-05-01&rft.volume=1794&rft.issue=5&rft.spage=769&rft.epage=781&rft.pages=769-781&rft.issn=1570-9639&rft.eissn=1878-1454&rft_id=info:doi/10.1016/j.bbapap.2008.10.004&rft_dat=%3Cproquest_pubme%3E20672206%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20672206&rft_id=info:pmid/19026770&rft_els_id=S1570963908003348&rfr_iscdi=true |